According to the Centers for Disease Control and Prevention, the global Idiopathic Hypersomnia Treatment Market is expected to grow at a 2.4 percent annual rate during the forecast period due to the increasing incidence of neurological disorders that cause hypersomnia. For example, in the United States in 2018, approximately 7.1 percent of 317-year-olds (approximately 4.4 million) were diagnosed with hypersomnia.
In terms of distribution channels, the hospital pharmacy segment is expected to dominate the global market for the treatment of idiopathic hypersomnia. The increase in a hospital or clinic visits due to lifestyle conditions such as anxiety, depression, and the increase in the number of hospitals are some of the main factors. responsible for the growth of the hospital pharmacy segment.